Francisco Poyales1, Nuria Garzon2. 1. IOA Madrid Innova Ocular, Madrid, Spain. 2. IOA Madrid Innova Ocular, Madrid, Spain. Electronic address: ngarzon@ioamadrid.com.
Abstract
PURPOSE: To evaluate visual outcomes and satisfaction after implantation of 2 trifocal intraocular lenses (IOLs): a spherical IOL and a toric IOL. SETTING: IOA Madrid Innova Ocular, Madrid, Spain. DESIGN: Prospective, controlled clinical trial. METHODS: Patients (>50 years) were implanted bilaterally with either a trifocal spherical hydrophilic IOL (FineVision POD F) if corneal astigmatism was 1.0 diopter (D) or less, or with a trifocal toric hydrophilic IOL (FineVision POD FT) if astigmatism was more than 1.0 D. Outcomes analyzed 3 months after surgery included monocular and binocular visual acuities at distance, near, and intermediate, both uncorrected and corrected. Defocus curves, contrast sensitivity, and patient satisfaction were also assessed. RESULTS: There was no statistically significant difference between groups in monocular uncorrected distance (UDVA) (P = .38), monocular corrected distance (CDVA) (P = .22), or distance-corrected intermediate (DCIVA) (P = .95) visual acuities; however, the distance-corrected near visual acuity (DCNVA) was slightly better in the spherical IOL group (P = .008). The UDVA was 20/25 or better in 89% of eyes in the spherical IOL group and 93% in the toric IOL group. The DCIVA was 20/32 or better in 92% of eyes in the spherical IOL group and 93% in the toric IOL group at 80 cm (Radner Vissum chart), and 20/32 or better in 100% of eyes in both groups at 63 cm (Colenbrander chart). The DCNVA (Radner chart) was 20/32 or better in 89% of eyes in the spherical IOL group and 90% of eyes in the toric IOL group. There was no difference between the groups in contrast sensitivity, defocus curves, cylinder, or satisfaction results. CONCLUSION: Patients had significant improvement in visual acuity and gained functional uncorrected visual acuity across all distances in both groups. Satisfaction was high with both IOLs.
RCT Entities:
PURPOSE: To evaluate visual outcomes and satisfaction after implantation of 2 trifocal intraocular lenses (IOLs): a spherical IOL and a toric IOL. SETTING: IOA Madrid Innova Ocular, Madrid, Spain. DESIGN: Prospective, controlled clinical trial. METHODS:Patients (>50 years) were implanted bilaterally with either a trifocal spherical hydrophilic IOL (FineVision POD F) if corneal astigmatism was 1.0 diopter (D) or less, or with a trifocal toric hydrophilic IOL (FineVision POD FT) if astigmatism was more than 1.0 D. Outcomes analyzed 3 months after surgery included monocular and binocular visual acuities at distance, near, and intermediate, both uncorrected and corrected. Defocus curves, contrast sensitivity, and patient satisfaction were also assessed. RESULTS: There was no statistically significant difference between groups in monocular uncorrected distance (UDVA) (P = .38), monocular corrected distance (CDVA) (P = .22), or distance-corrected intermediate (DCIVA) (P = .95) visual acuities; however, the distance-corrected near visual acuity (DCNVA) was slightly better in the spherical IOL group (P = .008). The UDVA was 20/25 or better in 89% of eyes in the spherical IOL group and 93% in the toric IOL group. The DCIVA was 20/32 or better in 92% of eyes in the spherical IOL group and 93% in the toric IOL group at 80 cm (Radner Vissum chart), and 20/32 or better in 100% of eyes in both groups at 63 cm (Colenbrander chart). The DCNVA (Radner chart) was 20/32 or better in 89% of eyes in the spherical IOL group and 90% of eyes in the toric IOL group. There was no difference between the groups in contrast sensitivity, defocus curves, cylinder, or satisfaction results. CONCLUSION:Patients had significant improvement in visual acuity and gained functional uncorrected visual acuity across all distances in both groups. Satisfaction was high with both IOLs.
Authors: Diego Montagud-Martínez; Vicente Ferrando; Anabel Martínez-Espert; Salvador Garcia-Delpech; Juan A Monsoriu; Walter D Furlan Journal: J Clin Med Date: 2022-02-24 Impact factor: 4.241